Pfizer and eFFECTOR Therapeutics inked a global license and collaboration deal to develop small-molecule inhibitors of eukaryotic initiation factor 4E, also known as eIF4E.
Paris-based Sanofi is acquiring San Diego-based immuno-oncology company Synthorx for $68 per share in cash, representing a value of $2.5 billion.
Netherlands-based Kiadis Pharma is discontinuing Phase III development of lead T-cell asset ATIR101 and laying off half of the company’s staff, seven months after acquiring CytoSen.
Thousand Oaks, California-based Amgen significantly expanded the company’s presence in China by taking a 20.5 percent stake in BeiGene Co.
Leeds, UK-based 4D Pharma and Merck/MSD are developing Live Biotherapeutics vaccines, a new class of medicines.
Adicet Bio Inc., a biopharmaceutical company focused on the development of cancer therapies using gamma delta T cells, raised $80 million in private funding.
Amphivena Therapeutics Inc., a private clinical stage immuno-oncology company developing T-cell engager therapeutics for cancer, announced the closing of a $62 million Series C financing.
Celgene and Immatics Biotechnologies inked a deal to develop novel adoptive cell therapies targeting multiple cancers.
ImmunoGen shares fell after the company announced the slashing of 220 employees as part of an effort to reduce ongoing expenses while recovering from an FDA rejection of an ovarian cancer drug.
The IQVIA Institute for Human Data Science is releasing the 2019 “Global Oncology Trends” report simultaneously with the American Society of Clinical Oncology (ASCO) Meeting.